Investors / United States / Remiges Ventures
Remiges Ventures
Venture capital · Seattle, WA, United States · North America
Remiges Ventures is an investment firm with offices in Seattle and Tokyo. It manages the RDiscovery Fund, which incubates drug discovery seeds, and holds portfolio companies in biopharmaceutical development.
Invests inHealthcare & Biotech
In its own wordsbiotechdrug discoverylife sciencesincubationpharmaceuticals
Your fit with Remiges Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRemiges Ventures lists 16 checked portfolio companies on its own site and is named in 2 funding rounds, 1 of them as lead. Its most frequent entry is Seed, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 46% of its companies are based in United States. It invests most often alongside Asahi Kasei Ventures, Kyoto University Innovation Capital and Lumira Ventures.
Counts come from funding rounds that name Remiges Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Remiges Ventures' whole history. Rounds on record name 2 companies; its own site lists 16. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundRemiges Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 50% |
| Series A | 0% |
| Series B | 0% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 42th | 16 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 73th | 50% of entries at pre-seed or seed |
| Evidence | 83th | 13% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Asahi Kasei Ventures | 2 |
| Kyoto University Innovation Capital | 2 |
| Lumira Ventures | 2 |
| AN Venture Partners | 1 |
| Abingworth | 1 |
| Advent Life Sciences | 1 |
| Ajinomoto Group Ventures | 1 |
| Astellas Venture Management | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers16100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Asahi Kasei Ventures
Compare Remiges Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Remiges Ventures| Date | Company | Stage |
|---|---|---|
| 31 Dec 2025 | Seed Led | |
| 16 Apr 2025 | Series C+ |
Round details for Remiges Ventures
Amounts, full round histories and every co-investor in Remiges Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
16 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Capacity Bio develops small molecules, peptides, and nanoparticles to enhance identification of dysfunctional mitochondria and promote clearance by autophagosomes and lysosomes | Healthcare & Biotech | Portfolio page | ||
| Cyrano Therapeutics develops therapies for people dealing with long-term loss of smell and taste. | Healthcare & Biotech | Portfolio page | ||
| ENB Therapeutics develops small molecules to treat drug-resistant cancers by targeting the tumor microenvironment | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Enemsa Pharma develops therapies for neurodegenerative diseases | Healthcare & Biotech | Dec 2025Seed | Page + round | |
| Glycomine is developing replacement therapies for rare genetic diseases | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| IMEL Biotherapeutics is developing a novel mitochondrial replacement approach for cell-based therapies | Healthcare & Biotech | Portfolio page | ||
| Immunis Biomedical is a clinical-stage biotech developing therapeutics targeting age-related disease | Healthcare & Biotech | Portfolio page | ||
| Kisoji Biotechnology discovers and develops highly differentiated antibody therapeutics to address difficult targets in oncology and other diseases. | Healthcare & Biotech | Portfolio page | ||
| Kupando develops therapies to address critical unmet medical needs in cancer and infectious diseases | Healthcare & Biotech | Portfolio page | ||
| LUCA Science is a pre-clinical stage biotechnology company focused on developing functional mitochondria as therapeutic agents | Healthcare & Biotech | Portfolio page | ||
| Myrodia Therapeutics develops preventive and therapeutic drugs using olfactory components | Healthcare & Biotech | Portfolio page | ||
| NapaJen Pharma develops and researches bio pharmaceuticals with a focus on nucleic acid medicine delivery technology | Healthcare & Biotech | Portfolio page | ||
| Omeicos Therapeutics is focused on developing therapies for cardiovascular, inflammatory and mitochondrial diseases | Healthcare & Biotech | Portfolio page | ||
| Restore Vision develops a visual restoration gene therapy | Healthcare & Biotech | Portfolio page | ||
| Viage Therapeutics is a neuroscience company that develops novel neurotherapeutics, including a clinical drug candidate targeting the gut-brain axis. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- remigesventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Apr 2025
- Companies checked
- 16
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Remiges Ventures' profile as data
Pull Remiges Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/remigesventures.com
# also
GET /v1/firms/remigesventures.com/portfolio
GET /v1/firms/remigesventures.com/coinvestors
GET /v1/firms/remigesventures.com/news